PDS Biotechnology/$PDSB
1D1W1MYTD1Y5YMAX
About PDS Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
- Ticker
- $PDSB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 21
- Headquarters
- Princeton, United States
- Website
- www.pdsbiotech.com
PDSB Metrics
BasicAdvanced
$12M
-
-$0.64
1.55
-
Price and volume
Market cap
$12M
Beta
1.55
52-week high
$1.55
52-week low
$0.20
Average daily volume
2M
Financial strength
Current ratio
0.569
Quick ratio
0.452
Long term debt to equity
-0.265
Total debt to equity
-121.899
Interest coverage (TTM)
-4.18%
Profitability
EBITDA (TTM)
-27.772
Management effectiveness
Return on assets (TTM)
-70.59%
Return on equity (TTM)
-543.97%
Valuation
Price to book
-3.29
Price to tangible book (TTM)
-3.29
Price to free cash flow (TTM)
-0.661
Free cash flow yield (TTM)
-151.29%
Free cash flow per share (TTM)
-0.319
Growth
Earnings per share change (TTM)
-29.71%
3-year earnings per share growth (CAGR)
-26.49%
What the Analysts think about PDSB
Analyst ratings (Buy, Hold, Sell) for PDS Biotechnology stock.
PDSB Financial Performance
Revenues and expenses
PDSB Earnings Performance
Company profitability
PDSB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.